Indication

Maximum Tolerated Dose

1 clinical trial

1 product

1 drug

Clinical trial

A Multicenter, Phase Ib/II Trial of Selinexor as a Single Agent and in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GISTs)

Status: Active (not recruiting), Estimated PCD: 2023-04-16

Drug

Product